NASDAQ · RPHM
Healthcare · Biotechnology
$18.20
Up+$16.47 (+952.02%)
Updated Aug 25, 2026, 3:45 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RPHM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RPHM.
RPHM research
Company profile and research snapshot.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2023 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2023 | Jefferies | Hold | — |
| Dec 15, 2023 | Leerink Partners | Market Perform | — |
| Nov 15, 2023 | William Blair | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 4, 2024
OnKure, a clinical-stage biopharmaceutical company, has completed its merger with Reneo Pharmaceuticals and raised $65 million in a private placement. The combined company will focus on developing a pipeline of candidates targeting oncogenic mutations in PI3Kα, initially in breast cancer.
Benzinga · Oct 3, 2024
Reneo Pharmaceuticals announced that its stockholders have approved the proposed merger with OnKure, Inc. The combined company will focus on advancing OnKure's pipeline of oncology drug candidates.
GlobeNewswire Inc. · May 13, 2024
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology
GlobeNewswire Inc. · May 7, 2024
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RPHM.
No results
No recent SID articles mention RPHM.
